Estrogen-only hormone therapy may reduce Alzheimer's risk
Women receiving estrogen therapy during menopause showed fewer signs of dementia.
1Alzheimer's rate in women
Alzheimer's disease is twice as common in women than men. The exact reason is unknown, but factors like women's longer lifespan, genetics, or menopause effects are being considered. Jennifer Bruno from Stanford University notes that the sharp drop in estrogen levels may affect brain aging. This could be a factor increasing Alzheimer's risk.
2Study scope
Analyzing 21,462 patient records, the research found fewer signs of memory loss and cognitive decline in women receiving estrogen-only therapy for menopause. About 3,000 had donated their brains postmortem. Jacob Shaw from Massachusetts General Hospital emphasized accounting for factors like age, race, and hypertension. Those taking estrogen showed fewer Alzheimer's biomarkers in their brains.
3Biological findings
Examination of brain donors revealed fewer neurobiological hallmarks of Alzheimer's—like beta-amyloid plaques and tau protein tangles—in estrogen users. Living patients' data also showed reduced Alzheimer's-related biomarkers. However, researchers caution this doesn't prove causation.
4Study limitations
The study lacked data on why patients received estrogen-only therapy. Since estrogen alone may increase endometrial cancer risk, it's typically recommended for hysterectomized women—but hysterectomy records were unavailable. Stanford's Hadi Hosseini noted estrogen users might be healthier overall or have better healthcare access.
5Other hormone therapies
Some past studies suggest combination therapies (e.g., progesterone+estrogen) may increase dementia risk, though reasons remain unclear. Researchers stress the need for long-term studies on menopause, estrogen, and dementia. Bruno says this study lays groundwork for future controlled trials.
6Dataset analysis
Two datasets were used: one included nearly 3,000 postmortem brain donations; the other examined biomarkers in living patients. Both showed reduced Alzheimer's signs in estrogen users. Researchers emphasize these findings need confirmation via randomized controlled trials.
7Healthcare access factor
Hosseini suggests estrogen users might have better healthcare access, potentially improving overall health—which could independently reduce Alzheimer's risk. The study couldn't fully control for socioeconomic factors affecting health outcomes.
8Importance of future research
Researchers highlight the need for more studies—especially long-term patient tracking—to understand the menopause-Alzheimer's link. Bruno notes these findings set the stage for randomized controlled trials. If confirmed, menopause treatments could become part of Alzheimer's prevention strategies.